HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue.

Abstract
A recombinant antibody-lymphotoxin-alpha fusion protein induced an adaptive immune response protecting mice from melanoma. Importantly, this fusion protein elicited the formation of a lymphoid-like tissue in the tumor microenvironment containing L-selectin+ T cells and MHC class II+ antigen-presenting cells, as well as B and T cell aggregates. Furthermore, PNAd+/TCA4+ high endothelial venules were observed within the tumor, suggesting entry channels for naive T cell infiltrates. Over the course of therapy, a marked clonal expansion of certain TCR specificities occurred among tumor-infiltrating lymphocytes that displayed reactivity against melanoma cells and the TRP-2(180-188) peptide. Consequently, naive T cells may have been recruited to as well as primed and expanded in the lymphoid-like tissue induced by the lymphotoxin-alpha fusion protein at the tumor site.
AuthorsD Schrama, P thor Straten, W H Fischer, A D McLellan, E B Bröcker, R A Reisfeld, J C Becker
JournalImmunity (Immunity) Vol. 14 Issue 2 Pg. 111-21 (Feb 2001) ISSN: 1074-7613 [Print] United States
PMID11239444 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal
  • Immunotoxins
  • Lymphotoxin-alpha
  • Recombinant Fusion Proteins
Topics
  • Animals
  • Antibodies, Monoclonal (therapeutic use)
  • Endothelium, Lymphatic (immunology, pathology)
  • Humans
  • Immunotoxins (therapeutic use)
  • Lung Neoplasms (immunology, secondary, therapy)
  • Lymphocytes, Tumor-Infiltrating (immunology, pathology)
  • Lymphoid Tissue (immunology, pathology)
  • Lymphotoxin-alpha (therapeutic use)
  • Melanoma, Experimental (immunology, pathology, therapy)
  • Mice
  • Mice, Inbred C57BL
  • Microscopy, Electron
  • Neoplasm Transplantation
  • Neoplasms, Connective Tissue (immunology, pathology, therapy)
  • Recombinant Fusion Proteins (therapeutic use)
  • T-Lymphocytes (immunology, pathology)
  • Transplantation, Isogeneic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: